Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses.
Many individuals have been previously exposed to human adenovirus serotype 5 (Ad5). This prior immunity has long been known to hinder its use for gene therapy and as a gene-based vaccine. Given these immunogenicity problems, we have tested whether polyethylene glycol (PEG) can blunt immune effects against Ad5 during systemic and mucosal vaccination. Ad5 vectors were covalently modified with 5-, 20-, and 35-kDa linear PEG polymers and evaluated for their ability to produce immune responses against transgene antigen products and the vector itself. We show that shielding Ad5 with different-sized PEGs generally reduces transduction and primary antibody responses by the intramuscular or intranasal route. In contrast, PEGylated vectors generally appear better at boosting antibody responses in Ad-immune animals. Displaying either glucose or galactose on PEG mediated increased transduction and antibody responses by the intranasal, but not the intramuscular, route. In naive animals, PEGylated vectors generated T cell responses that were equal to or better than those by unmodified Ad. Priming by PEGylated vectors generally enabled better subsequent T cell responses after boost. Priming and boosting by PEGylated vectors produced T cell responses after boost that were equal to or higher than those produced by unmodified vectors. These data indicate that PEGylation can enable more effective application of Ad5 and perhaps other Ad serotype vaccines during prime-boost vaccination.
Weaver
Eric A
EA
Division of Infectious Diseases, Department of Internal Medicine, and Translational Immunovirology and Biodefense Program, Mayo Clinic, Rochester, MN 55902, USA.
Barry
Michael A
MA
D000256:Adenoviridae / Q000235:genetics* / Q000276:immunology; D000595:Amino Acid Sequence; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002478:Cells, Cultured; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005822:Genetic Vectors; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology*
D000914:Antibodies, Viral; D014765:Viral Vaccines; D011092:Polyethylene Glycols
Hum Gene Ther. 2007 Sep;18(9):837-48
17767399
Vaccine. 2006 Jun 5;24(23):5064-72
16621178
Mol Ther. 2004 Sep;10(3):432-46
15336644
Gene Ther. 2005 Apr;12(7):579-87
15647765
Immunity. 1994 Aug;1(5):433-42
7533647
Mol Ther. 2000 Mar;1(3):225-35
10933938
Hum Gene Ther. 2004 May;15(5):433-43
15144574
Mol Ther. 2008 Jan;16(1):154-62
17848961
J Exp Med. 2008 Jan 21;205(1):7-12
18195078
J Virol. 2001 May;75(10):4792-801
11312351
J Virol. 1996 Mar;70(3):1836-44
8627708
J Immunol. 1999 Jun 1;162(11):6716-23
10352290
Hum Gene Ther. 1999 May 20;10(8):1349-58
10365665
Mol Ther. 2003 Oct;8(4):688-700
14529842
Mol Ther. 2008 Jul;16(7):1276-82
18461056
J Clin Microbiol. 2003 Nov;41(11):5046-52
14605137
J Immunol. 2004 May 15;172(10):6290-7
15128818
Hum Gene Ther. 1999 Feb 10;10(3):395-406
10048392
Hum Gene Ther. 2005 May;16(5):634-41
15916488
Nature. 2006 May 11;441(7090):239-43
16625206
Nat Med. 1997 Jun;3(6):651-8
9176492
Hum Gene Ther. 1996 Apr 10;7(6):721-9
8919594
Mol Ther. 2001 May;3(5 Pt 1):708-22
11356076
Mol Ther. 2005 Jan;11(1):66-79
15585407
Hum Gene Ther. 2002 Oct 10;13(15):1887-900
12396620